141 results
424B3
QTTB
Q32 Bio Inc.
29 Apr 24
Prospectus supplement
5:10pm
bempikibart and ADX-097, and our anticipated milestones and timing therefor;
the benefits that may be derived from any of our future products … realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC before
10-K/A
2023 FY
EX-4.1
QTTB
Q32 Bio Inc.
12 Apr 24
Annual report (amended)
4:33pm
believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited
10-K/A
2023 FY
QTTB
Q32 Bio Inc.
12 Apr 24
Annual report (amended)
4:33pm
and 21E of the Exchange Act, including statements regarding the anticipated benefits of the Merger and the financial condition, results of operations … policies.
Employee Benefits
Homology’s named executive officers are eligible to participate in its employee benefit plans and programs, which include
10-K/A
2023 FY
EX-97.1
QTTB
Q32 Bio Inc.
12 Apr 24
Annual report (amended)
4:33pm
listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly
8-K
plbtpz fj1hq9zw5n
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.16
4qai1ed76 rodvh1a
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.7
g7gt mfju2d1er0s
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-99.5
f35tkr94hlyxy9xmsr
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-99.1
a9sk26kcar5mb0x12u
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.17
umq 359h8t
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.1
p33jexy3ye0 xnfj80a
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-99.4
2ucpnnx8n49tc
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.4
ayj8 8dk1a
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.15
e6t036ypwekz
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-99.6
bcavhssj83krm4euf
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.6
80g0hq8z
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.18
m47jjzbdk5d
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.9
4gkulkq1asrk2 qyfe54
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
8-K
EX-10.10
epalxa
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm